601 related articles for article (PubMed ID: 16249934)
41. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
[TBL] [Abstract][Full Text] [Related]
42. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
[TBL] [Abstract][Full Text] [Related]
43. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
[TBL] [Abstract][Full Text] [Related]
44. Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin.
Müller L; Murgia X; Siebenbürger L; Börger C; Schwarzkopf K; Sewald K; Häussler S; Braun A; Lehr CM; Hittinger M; Wronski S
J Antimicrob Chemother; 2018 Oct; 73(10):2762-2769. PubMed ID: 29982453
[TBL] [Abstract][Full Text] [Related]
45. The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa.
Oglesby-Sherrouse AG; Djapgne L; Nguyen AT; Vasil AI; Vasil ML
Pathog Dis; 2014 Apr; 70(3):307-20. PubMed ID: 24436170
[TBL] [Abstract][Full Text] [Related]
46. Neutral super-oxidised solutions are effective in killing P. aeruginosa biofilms.
Sauer K; Thatcher E; Northey R; Gutierrez AA
Biofouling; 2009; 25(1):45-54. PubMed ID: 18846439
[TBL] [Abstract][Full Text] [Related]
47. Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions.
Major TA; Panmanee W; Mortensen JE; Gray LD; Hoglen N; Hassett DJ
Antimicrob Agents Chemother; 2010 Nov; 54(11):4671-7. PubMed ID: 20696868
[TBL] [Abstract][Full Text] [Related]
48. Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions.
O'May CY; Sanderson K; Roddam LF; Kirov SM; Reid DW
J Med Microbiol; 2009 Jun; 58(Pt 6):765-773. PubMed ID: 19429753
[TBL] [Abstract][Full Text] [Related]
49. Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.
Tom SK; Yau YC; Beaudoin T; LiPuma JJ; Waters V
Antimicrob Agents Chemother; 2016 Jan; 60(1):650-2. PubMed ID: 26525791
[TBL] [Abstract][Full Text] [Related]
50. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms.
Maiden MM; Hunt AMA; Zachos MP; Gibson JA; Hurwitz ME; Mulks MH; Waters CM
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29661867
[TBL] [Abstract][Full Text] [Related]
51. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials.
Spoering AL; Lewis K
J Bacteriol; 2001 Dec; 183(23):6746-51. PubMed ID: 11698361
[TBL] [Abstract][Full Text] [Related]
52. High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms.
Hengzhuang W; Ciofu O; Yang L; Wu H; Song Z; Oliver A; Høiby N
Antimicrob Agents Chemother; 2013 Jan; 57(1):196-204. PubMed ID: 23089750
[TBL] [Abstract][Full Text] [Related]
53. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
54. The impact of anaerobiosis on strain-dependent phenotypic variations in Pseudomonas aeruginosa.
Fang H; Toyofuku M; Kiyokawa T; Ichihashi A; Tateda K; Nomura N
Biosci Biotechnol Biochem; 2013; 77(8):1747-52. PubMed ID: 23924741
[TBL] [Abstract][Full Text] [Related]
55. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
[TBL] [Abstract][Full Text] [Related]
56. Persister cells, the biofilm matrix and tolerance to metal cations in biofilm and planktonic Pseudomonas aeruginosa.
Harrison JJ; Turner RJ; Ceri H
Environ Microbiol; 2005 Jul; 7(7):981-94. PubMed ID: 15946294
[TBL] [Abstract][Full Text] [Related]
57. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
Price KE; Naimie AA; Griffin EF; Bay C; O'Toole GA
J Bacteriol; 2016 Jan; 198(2):237-47. PubMed ID: 26483523
[TBL] [Abstract][Full Text] [Related]
58. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
Maiden MM; Zachos MP; Waters CM
J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
[TBL] [Abstract][Full Text] [Related]
59. Pseudomonas aeruginosa is oxygen-deprived during infection in cystic fibrosis lungs, reducing the effectiveness of antibiotics.
Martin LW; Gray AR; Brockway B; Lamont IL
FEMS Microbiol Lett; 2023 Jan; 370():. PubMed ID: 37516450
[TBL] [Abstract][Full Text] [Related]
60. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Shawar RM; MacLeod DL; Garber RL; Burns JL; Stapp JR; Clausen CR; Tanaka SK
Antimicrob Agents Chemother; 1999 Dec; 43(12):2877-80. PubMed ID: 10582875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
